KOSDAQBiotech & Pharma226950

OliX Pharmaceuticals

₩78,600▲ 0.26%2026-11-18 close
Market Cap
₩1.8T
Turnover
₩6.1B
Volume
80K
Shares out.
22.9M
PER
—
PBR
7.8×
EPS
-₩653
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Pipeline Expansion Amid Continued Operating Losses

OliX Pharmaceuticals holds an RNAi platform pipeline and licensing track record, but operating losses have continued for five straight quarters through the third quarter of 2026.

  1. 1

    On a filed basis, annual sales peaked at KRW 17.1 billion in 2023, fell to KRW 5.68 billion in 2024, and recovered to KRW 14.7 billion in 2025.

  2. 2

    Operating losses have been recorded for four consecutive years from 2022 to 2025, and the third-quarter 2026 operating loss widened to KRW 16.3 billion.

  3. 3

    Net profit attributable to controlling shareholders turned positive at KRW 15.4 billion in the fourth quarter of 2025, while the operating loss that quarter was KRW 8.46 billion, suggesting a large non-operating effect.

  4. 4

    The pipeline runs from the Eli Lilly licensing of OLX702A to the OLX301A Phase 2a IND filing in September 2026 and the target to enter Phase 1 of OLX501A in the first half of 2027.

  5. 5

    PER cannot be calculated because the last four quarters show a net loss, and the price-to-book ratio sits in a range with a large premium over net assets.

02

Business structure

OliX Pharmaceuticals is a biotech company that discovers drug candidates using its RNA interference (RNAi) platform, OASIS, and licenses them to global pharmaceutical companies or co-develops them.

The company has set out an 'OliX 2.0' roadmap to extend its pipeline from liver, skin and eye targets to fat tissue, the central nervous system (CNS), kidney and muscle. Its lead program, OLX702A for MASH and obesity, was licensed to Eli Lilly in February 2025, and Lilly is set to lead development from Phase 2.

The macular degeneration candidate OLX301A received the final clinical study report for its US Phase 1 trial in November 2025, and in September 2026 the company filed an Australian Phase 2a trial application for dry macular degeneration.

The alopecia candidate OLX104C has completed dosing and follow-up in an Australian Phase 1b study. The obesity candidate OLX501A, the first program on its fat-tissue platform, was described by the company as having about three times the visceral fat reduction of a competitor compound in primate preclinical studies.

In July 2026 the company also unveiled OASIS-DUO, a platform that delivers siRNA to two organs with one drug. Partners include Eli Lilly and L'Oréal, and discussions with several global pharmaceutical companies on the macular degeneration candidate are ongoing.

Segment-level revenue is not included in the filed results table, so the revenue mix cannot be compared by segment. The company positions its RNAi candidates as addressing the muscle loss and weight rebound limits of GLP-1 obesity drugs.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.9B-₩8.3B−285.7%
2025Q4₩4.5B-₩8.5B−186.7%
2026Q1₩3.6B-₩10.8B−301.9%
2026Q2₩2.6B-₩14B−533.3%
2026Q3₩2.2B-₩16.3B−754.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩9.3B-₩22.4B-₩19.5B−240.1%−29.6%100.4%
2023₩17.1B-₩18.2B-₩19.1B−106.6%−38.3%104.3%
2024₩5.7B-₩30.9B-₩40.7B−544.6%−227.8%285.7%
2025₩14.7B-₩30B-₩15.7B−204.4%−10.5%30.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual sales rose from KRW 9.32 billion in 2022 to KRW 17.1 billion in 2023, an increase of 83.1%, fell to KRW 5.68 billion in 2024, a decrease of 66.7%, and recovered to KRW 14.7 billion in 2025, an increase of 158.3%. Among 2022 to 2025, 2023 was the largest year and 2024 the smallest.

Operating losses were KRW 22.4 billion in 2022, KRW 18.2 billion in 2023, KRW 30.9 billion in 2024 and KRW 30 billion in 2025, and operating margins were -240.1%, -106.6%, -544.6% and -204.4%, respectively.

The largest operating loss came in 2024, the year sales were smallest, and in 2025 the operating loss narrowed to KRW 30 billion as sales recovered. Net loss attributable to controlling shareholders was KRW 19.5 billion in 2022, KRW 19.1 billion in 2023, KRW 40.7 billion in 2024 and KRW 15.7 billion in 2025.

Total net loss including non-controlling interests was KRW 21.9 billion in 2022, so the non-controlling share sat on the loss side that year. Quarterly sales peaked in the fourth quarter of 2025 at KRW 4.53 billion, up 55.8% from the prior quarter.

They then declined for three straight quarters to KRW 3.57 billion in the first quarter of 2026, KRW 2.62 billion in the second and KRW 2.16 billion in the third, which was down 25.7% from a year earlier.

Operating losses widened from KRW 8.31 billion in the third quarter of 2025 to KRW 8.46 billion, KRW 10.8 billion, KRW 14 billion and KRW 16.3 billion in the third quarter of 2026.

Net profit attributable to controlling shareholders turned positive at KRW 15.4 billion in the fourth quarter of 2025, while that quarter's operating loss was KRW 8.46 billion, which points to a sizable non-operating effect.

Net losses attributable to controlling shareholders followed at KRW 9.77 billion, KRW 11 billion and KRW 12.2 billion across the first three quarters of 2026, and the last four quarters total KRW 17.5 billion in net losses.

Operating cash flow was negative in every year from 2022 to 2025, at -KRW 30.7 billion, -KRW 21.2 billion, -KRW 28 billion and -KRW 15.9 billion. Total equity at the end of 2025 was KRW 150.1 billion and total liabilities were KRW 45.3 billion, so the debt ratio fell from 285.7% in 2024 to 30.2% in 2025.

05

Industry analysis

The Korean biotech sector was volatile in March 2026, when Middle East geopolitical risk pushed the KRX Healthcare Index down 10%.

OliX's share price rose 2.83% that month, which was reported as an outperformance against a weak sector, and the company attributed this to the combination of expectations on its core pipeline and data on newer candidates.

In obesity and metabolic disease, GLP-1 drugs set the reference point, and follow-on candidates are competing to address muscle loss and weight rebound.

The company said primate data for OLX501A were on par with or better than a competing RNAi compound, and that combined use with GLP-1 drugs defended against or eased rebound and muscle loss.

In an August 2026 assessment, IVResearch said the first phase of OliX's platform had secured clinical data and global partnerships in the liver, skin and eye. The same report described the OliX 2.0 strategy as widening the tissues RNAi can reach and the range of targets one drug can control. These assessments precede confirmed clinical results.

06

Outlook

OLX702A is at the close of its Australian Phase 1b study, and in a July 2026 announcement the company expected to receive the final clinical study report for Phase 1 in the second half of 2026. Eli Lilly is expected to take over the subsequent Phase 2 development.

The company said the single-dose stage showed a liver fat reduction effect lasting more than 10 months. The alopecia candidate OLX104C is expected to complete its Phase 1b study in the second half of 2026, with a Phase 2a target of completion within 2027.

OLX301A's Australian Phase 2a IND was filed in September 2026, and Lilly will lead development from Phase 2. The obesity candidate OLX501A targets entry into Phase 1 in the first half of 2027, and the company said a licensing deal could come even before clinical entry.

Apart from clinical work, the company said it is in discussions on licensing, co-development and NewCo formation with several potential partners. The IND submission target for the ALK7 program is 2027. The next filed report, the 2026 annual report, will show full-year sales, operating loss and operating cash flow.

07

Valuation

PER
—
PBR
7.8×
ROE
-9.3%
EPS
-₩653
BPS
₩10,417
Dividend per share
₩0

The price-to-book ratio sits in a range with a large premium over net assets, with the market value well above total equity of KRW 150.1 billion and controlling-shareholder equity of KRW 149.4 billion. That gap can be read as the market valuing the pipeline and licensing potential rather than current earnings.

PER cannot be calculated because the last four quarters total a net loss attributable to controlling shareholders of KRW 17.5 billion. Dividends are effectively absent, so the dividend yield sits below the sector average.

Operating cash flow has been negative every year since 2022, so the gap between capital base and cash generation matters. The debt ratio fell to 30.2%, which reflects lower leverage, but continued losses could erode equity and push the ratio back up. Valuation for this company is tied to clinical results and licensing terms.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Pipeline spread across clinical stages

OLX702A is at the end of its Phase 1b study, OLX301A has filed a Phase 2a IND, and OLX104C is nearing the end of Phase 1b. The company said OLX501A showed roughly three times the visceral fat reduction of a competitor compound in preclinical studies. Having several indications across clinical stages spreads reliance across programs rather than one readout.

Global partnerships and licensing track record

OLX702A was licensed to Eli Lilly in February 2025, and Lilly is set to lead development from Phase 2. The company also works with L'Oréal, and it said several global pharmaceutical companies are in partnering talks on the macular degeneration candidate.

Business development discussions on licensing, co-development and NewCo formation are running alongside clinical work.

Balance sheet and narrowing losses in 2025

Total equity at the end of 2025 was KRW 150.1 billion against total liabilities of KRW 45.3 billion, and the debt ratio fell from 285.7% in 2024 to 30.2% in 2025.

The annual operating loss narrowed from KRW 30.9 billion in 2024 to KRW 30 billion in 2025, and the net loss attributable to controlling shareholders narrowed from KRW 40.7 billion to KRW 15.7 billion. Net profit attributable to controlling shareholders turned positive at KRW 15.4 billion in the fourth quarter of 2025.

09

Bear factors

Widening quarterly operating losses

Operating losses widened from KRW 8.31 billion in the third quarter of 2025 to KRW 16.3 billion in the third quarter of 2026, and the company has recorded losses for five straight quarters. The third-quarter 2026 operating loss was wider than a year earlier.

Net losses attributable to controlling shareholders also continued for three straight quarters through the first three quarters of 2026.

Sales declines in recent quarters

Sales peaked at KRW 4.53 billion in the fourth quarter of 2025 and then fell to KRW 3.57 billion, KRW 2.62 billion and KRW 2.16 billion over the next three quarters. Falling sales alongside wider operating losses suggests the revenue base has not yet stabilized.

Negative cash flow and a high valuation multiple

Operating cash flow was negative in each year from 2022 to 2025, and it was -KRW 15.9 billion in 2025. The last four quarters total KRW 17.5 billion in net losses attributable to controlling shareholders.

The price-to-book ratio sits in a range with a large premium over net assets, so a disappointing clinical readout could lead to a sharp reset in that premium.

10

Risk factors

Clinical outcome risk

Lead programs including OLX702A, OLX104C and OLX301A remain in early or mid clinical stages, and readout timing depends on company targets. Weak efficacy or a safety signal could affect both licensing terms and valuation. Development after Phase 2 passes to partners such as Eli Lilly, so the pace also depends on those partners.

Licensing timing and terms

The company expects licensing could happen even before OLX501A enters clinical trials, but the timing and terms of any deal are not fixed. If licensing income is a major driver of sales and profit, earnings could remain volatile until deals are announced. A delay in securing partners could extend the period of operating losses.

Funding needs and market volatility

Operating cash flow has been negative for four straight years and the operating loss has widened in 2026, so additional funding could be needed to cover development costs. The biotech sector is sensitive to geopolitical shocks, as the KRX Healthcare Index fell 10% in March 2026. Shifts in sector-wide sentiment could add to share price volatility.

11

What to watch next

  1. By end of December 2026

    Confirm whether OLX702A receives its Phase 1 final clinical study report and OLX104C completes Phase 1b in the second half of 2026, as targeted. The confirmed safety and durability data will shape partner discussions.

  2. By March 31, 2027

    The 2026 annual report will show full-year sales, operating loss, operating cash flow and capital structure. The key question is how the quarterly sales decline is reflected in the full-year figures.

  3. First half of 2027

    Check whether the OLX501A Phase 1 IND is filed and whether the trial starts. Whether a licensing or co-development deal is disclosed around this period is also a key checkpoint.

  4. Within 2027

    Track the targeted end of the OLX104C Phase 2a study and the progress of the OLX301A Phase 2a study. Phase 2a results will shape the development path for the alopecia and macular degeneration indications.

12

Overall view

OliX Pharmaceuticals has built a pipeline across liver, eye, skin and fat-tissue targets, with clinical programs at different stages and a licensing track record with Eli Lilly.

The debt ratio fell to 30.2% at the end of 2025, and net profit attributable to controlling shareholders turned positive in the fourth quarter of 2025.

On the other side, the operating loss widened to KRW 16.3 billion in the third quarter of 2026 and has been recorded for five straight quarters, while sales have declined for three straight quarters. Operating cash flow has been negative for four straight years.

The price-to-book ratio sits in a range with a large premium over net assets, so clinical outcomes and licensing terms are central to how the valuation evolves.

The next checkpoints are the OLX702A Phase 1 final report expected in the second half of 2026, the operating loss in the 2026 annual report due by March 31, 2027, and the OLX501A IND filing in the first half of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. orix.co.jp
  2. comp.fnguide.com
  3. kr.investing.com
  4. kr.investing.com
  5. kr.investing.com
  6. tradingkey.com
  7. investing.com
  8. indexbox.io
  9. mt.co.kr
  10. mt.co.kr
  11. press9.kr
  12. sportalkorea.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. ncbi.nlm.nih.gov

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis